Category Archives: Articles

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today reported further progress in its continuing preclinical program of its CF602 drug candidate as the Company prepares to file an investigational new drug (IND) application...

Immune Pharmaceuticals Inc. (NASDAQ: IMNP) announced today that it has initiated its Phase II Ulcerative Colitis clinical trial and is scheduled to initiate its Phase II Bullous Pemphigoid clinical trial on July 1, 2015. Study Initiation is the training of hospital staff to allow for patient screening and immediate patient...

RedHill Biopharma announced positive top-line results from its Phase III study with RHB-105 for the treatment of Helicobacter pylori (H. pylori) bacterial infection. Top-line results from the study demonstrated 89.4% efficacy in eradicating H. pylori infection with RHB-105. The ERADICATE Hp first Phase III study successfully met its primary endpoint...

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), announced favorable data from further analysis of its Phase II/III double-blind, placebo-controlled study designed to test the efficacy of CF101 in patients with moderate-to-severe plaque psoriasis. The study included 326 patients through 17 clinical centers in the U.S., Europe, and Israel with...

Gour Medical SA, a veterinary biomedical company founded by Israeli entrepreneur Serge Goldner, has entered into a definitive worldwide license agreement with Actelion Pharmaceuticals Ltd for the veterinary development of one of Actelion’s early-stage clinical dual orexin receptor antagonists, which the company had decided not to pursue further. Gour plans...

BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), is about to start a Phase 2b trial for BL-8040 as a novel consolidation treatment for acute myeloid leukemia (AML). The Phase 2b study will examine its ability to improve outcomes for AML patients who have achieved remission after standard treatment by eliminating the...

Pluristem Therapeutics Inc. (NasdaqCM: PSTI) TASE: PSTI) has shown strong positive data from a preclinical study of PLX-R18 cells to improve outcomes of bone marrow transplantation. In the study, conducted in conjunction with Hadassah Medical Center’s Department of Bone Marrow Transplantation and Cancer Immunotherapy, mice with damaged bone marrow who...

Israeli-American biotech Chiasma has raised $70 million as it moves toward FDA approval with a treatment for the hormone disorder acromegaly. With the money, Chiasma plans to file an FDA application for oral octreotide, a treatment for the rare disorder. The company expects to submit the drug next quarter and,...

Submissions are now open for the EUROPEAN BIOTECHNICA AWARD. The coveted award will go to a European company that has introduced a disruptive technology in the field of biotechnology or the life sciences and has demonstrably shepherded it through to successful commercialization. The EUROPEAN BIOTECHNICA AWARD is offered by Deutsche...

Gamida Cell, a developer of cell therapy technologies and products for transplantation and adaptive immune therapy, announced that orphan drug designation has been granted by the FDA for its investigational medicinal product NiCord. The drug is used for the treatment of acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Hodgkin...

Ramat Gan-based EarlySense, which provides solutions for contact-free patient monitoring, announced today that it has completed a $20 million financing round, led by Samsung Ventures with an investment of $10 million. Existing investors whose participation was also substantial include Pitango Venture Capital, Welch Allyn, JK&B, Proseed and Noaber. “We are...

Sarah Furie, a veteran specialist in the field of drug and medical device regulation and registration, is offering a course on the subject in collaboration with Tel Aviv University starting March 8. For more info tadan1@netvision.net.il...

cCAM Biotherapeutics has started a Phase 1 trial assessing the effect of the CM-24 mAb on cancer patients with advanced or recurrent malignancies, including melanoma, non-small-cell lung, bladder, gastric, colorectal and ovarian cancers. The main objectives of the study are to assess the safety and tolerability of CM-24 and to...

Surgical Theater has been nominated as a finalist in the 2015 Everyday Health Awards for innovation in digital health and wellness solutions. The company was founded by former Israeli Air Force officers Alon Geri and Moty Avisar in 2010, developed a revolutionary brain surgery simulation method for doctors. Much like...

Bio-Chem recently expanded it’s services to include Pharmaceutical and Medical Device registration and regulation services in the US and Europe. The company provides GxP, Validation, Engineering, Quality Assurance, project management services & consultancy for companies from the pharmaceutical, biotechnology, medical device, cosmetics and food industries. Bio-Chem’s registration and regulation services...

The Chinese government offers a discount to exhibitors at BIOTECH CHINA for those who register through BioIsrael. BIOTECH CHINA is held once a year, combining business, commerce, matchmaking, communications, and technology. BIOTECH CHINA 2015 will include well-known companies as well as representative industry parks, hospitals and universities. There will be...

Rehovot-based NeuroDerm, which has developed a transdermal drug delivery system for the treatment of Parkinson’s disease, raised $45 million by issuing 4.5 million shares at $10 per share, giving it a company value of $164 million, after money. The amount raised could rise to $50 million, if the underwriters take...

D-Pharm Ltd (TASE: DPRM) has raised 12.8M NIS in aggregate. D-Pharm’s largest shareholder, CLAL Biotechnology (CBI), exercised all its rights to the tune of 8.7M NIS and a third of the total funds raised were from the public. D-Pharm is a clinical-stage neuroscience company focused on the development of pioneering...

Zingenix, previously known as ILIT Bio Ventures Ltd is  continuing its    development programs, focusing on gene therapy for severe orphan disorders including DMD(Ducehenne Muscular Dystrophy) ,using artificial transcription factors technologies. The company has raised a seed round of funding and has been joined by Dr. Robert Heft from Canada who has...